FILING ANALYSIS · MONDAY, NOVEMBER 9
AN2 Therapeutics, Inc. ANTX — 8-K: Results of Operations and Financial Condition
neutral
The company reported progress in its clinical pipeline, including FDA clearance for a global Phase 2 study of epetraborole in polycythemia vera and enrollment ongoing in a Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease, but no quantified surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →